How Cholesterol Is Managed: Diet, Statins, and Cardiovascular Risk

This article is for informational purposes only. Consult a qualified healthcare professional for medical advice, diagnosis, or treatment.

What Is Cholesterol and Why Does It Matter?

Cholesterol is a waxy, fat-like sterol that is essential for life — it is a structural component of every cell membrane, a precursor to steroid hormones (cortisol, testosterone, estrogen), bile acids, and vitamin D. The body produces approximately 70–80% of its cholesterol endogenously (primarily in the liver), while the remaining 20–30% comes from dietary sources. Despite its vital roles, chronically elevated blood cholesterol — particularly low-density lipoprotein (LDL) cholesterol — is a major causal risk factor for atherosclerosis and coronary heart disease (CHD). Cardiovascular disease (CVD) remains the leading cause of death globally, responsible for approximately 17.9 million deaths per year. Elevated LDL-C is estimated to cause 56% of global ischemic heart disease events, making cholesterol management one of the most impactful areas in preventive medicine.

Cholesterol Transport: Lipoproteins

Cholesterol is transported in the blood as part of lipoprotein particles — complexes of lipids and proteins (apolipoproteins). The key lipoproteins in clinical practice are:

Lipoprotein	Function	Cardiovascular Effect
Low-Density Lipoprotein (LDL)	Transports cholesterol from liver to peripheral tissues; takes up by cells via LDL receptors (LDLR)	Pro-atherogenic: oxidized LDL infiltrates arterial intima, taken up by macrophages, forms foam cells — the core of atherosclerotic plaques
High-Density Lipoprotein (HDL)	Reverse cholesterol transport: picks up cholesterol from peripheral tissues and delivers it back to the liver for excretion	Inversely associated with CVD risk epidemiologically; however, raising HDL pharmacologically has not consistently reduced CVD events
Very Low-Density Lipoprotein (VLDL)	Delivers triglycerides from liver to adipose and muscle tissue	Elevated VLDL/triglycerides associated with CVD risk, particularly in metabolic syndrome
Lipoprotein(a) [Lp(a)]	LDL-like particle with apolipoprotein(a) attached; genetically determined levels	Independent causal CVD risk factor; promotes thrombosis and atherosclerosis; not well addressed by standard lipid therapy

Atherosclerosis: The LDL-Disease Connection

The causal role of LDL in atherosclerosis is established through multiple converging lines of evidence: epidemiological studies, Mendelian randomization (using genetic variants as natural experiments), and clinical trials. The key insight from Mendelian randomization is that lifetime low LDL-C, regardless of how it is achieved, is associated with proportionally reduced CVD risk, and every 1 mmol/L (approximately 39 mg/dL) reduction in LDL-C reduces major cardiovascular events by approximately 22% per year of treatment.

Atherosclerosis begins when LDL particles — particularly oxidized LDL — infiltrate the subendothelial space of arterial walls, triggering macrophage recruitment and foam cell formation. Over decades, these lipid-laden plaques grow, become calcified, and may rupture, triggering thrombosis (clot formation) that acutely occludes the artery — the mechanism of most myocardial infarctions and strokes.

Assessing Cardiovascular Risk

Cholesterol management decisions are based on overall cardiovascular risk, not just cholesterol levels in isolation. Clinical tools such as the Pooled Cohort Equations (PCE) in the US and SCORE2 in Europe estimate 10-year ASCVD risk using age, sex, race, blood pressure, total and HDL cholesterol, diabetes status, and smoking. This risk estimate guides treatment thresholds and LDL targets:

Very high risk (established CVD, diabetes with organ damage, extreme risk factors): LDL target <1.4 mmol/L (55 mg/dL)
High risk (markedly elevated single risk factors, moderate CKD): LDL target <1.8 mmol/L (70 mg/dL)
Moderate/low risk: LDL targets <2.6 mmol/L (100 mg/dL) or <3.0 mmol/L (116 mg/dL)

Dietary Management

Diet influences LDL-C primarily through effects on hepatic LDL receptor expression and cholesterol synthesis:

Saturated Fats and Trans Fats

Saturated fatty acids (found in red meat, butter, cheese, coconut oil, and palm oil) raise LDL-C by down-regulating LDL receptor expression. Replacing saturated fat with polyunsaturated fat reduces LDL-C by approximately 0.1 mmol/L per 1% of energy substituted. Industrial trans fats (partially hydrogenated vegetable oils) both raise LDL and lower HDL — a particularly atherogenic combination. Trans fats have been largely phased out in developed countries following regulatory action, including their ban by the FDA in 2018.

Dietary Cholesterol

Dietary cholesterol has a smaller effect on blood LDL than saturated fat, because intestinal cholesterol absorption is regulated and the liver compensates by reducing synthesis. Recent evidence suggests dietary cholesterol has a modest and highly variable effect on LDL-C, and current guidelines have moved away from a strict numerical limit (the previous 300 mg/day recommendation was removed from the 2015–2020 Dietary Guidelines for Americans).

Portfolio Diet and Functional Foods

The Portfolio Diet, developed by Dr. David Jenkins, combines four food components proven to lower LDL: soluble fiber (oats, barley, psyllium — 5–10 g/day reduces LDL by ~5%); plant sterols/stanols (2 g/day reduce LDL by 6–10% by competing with cholesterol for intestinal absorption); nuts (25–40 g/day lower LDL by ~4%); and soy protein. Together, the Portfolio Diet reduces LDL-C by ~20–30%, approaching statin-level reductions in adherent individuals.

Pharmacological Management

Drug Class	Examples	LDL Reduction	Mechanism
Statins	Atorvastatin, rosuvastatin, simvastatin, pravastatin	30–60% (high-intensity: 50–60%)	Inhibit HMG-CoA reductase — the rate-limiting enzyme of hepatic cholesterol synthesis — upregulating LDL receptors
Ezetimibe	Ezetimibe (Zetia)	15–20% additional to statin	Blocks Niemann-Pick C1-Like 1 (NPC1L1) protein, reducing intestinal cholesterol absorption
PCSK9 inhibitors	Evolocumab (Repatha), alirocumab (Praluent)	50–65% additional to statin	Monoclonal antibodies binding PCSK9 — a protein that degrades LDL receptors; blocking PCSK9 increases LDL receptor recycling and availability
Inclisiran	Inclisiran (Leqvio)	~50% additional to statin	siRNA molecule silencing hepatic PCSK9 mRNA; twice-yearly injection
Bile acid sequestrants	Cholestyramine, colesevelam	10–20%	Bind bile acids in the gut, interrupting enterohepatic circulation; liver converts more cholesterol to bile acids
Bempedoic acid	Nexletol, Nexlizet	15–25% additional to statin/ezetimibe	Inhibits ATP-citrate lyase, upstream of HMG-CoA reductase; pro-drug activated only in the liver (fewer muscle side effects)

Statins: The Foundation of Lipid Therapy

Statins are among the most widely prescribed medications in history and have one of the strongest evidence bases in medicine. The Cholesterol Treatment Trialists' (CTT) Collaboration meta-analysis of 26 randomized trials involving 170,000 patients showed that each 1 mmol/L reduction in LDL-C with statins reduces major vascular events by 22% annually, with consistent benefits across all risk groups. High-intensity statins (atorvastatin 40–80 mg; rosuvastatin 20–40 mg) are standard in high-risk patients. Side effects are generally mild; the most clinically relevant is statin-associated muscle symptoms (myalgia) in approximately 5–10% of patients, though true severe myopathy and rhabdomyolysis are rare (<1 in 10,000). The cardiovascular mortality benefits of statins in high-risk populations substantially outweigh their risks.